Molecular determinants of breast cancer malignancy

描述（由申请方提供）：肿瘤细胞表达的癌蛋白骨桥蛋白（OPN）增强其恶性特性，特别是通过影响其生长、侵袭和转移的能力。我们的研究表明，OPN下调肿瘤抑制蛋白Merlin的蛋白水平，可能是通过靶向它在乳腺癌细胞中降解。Merlin是一种肿瘤抑制基因，在神经系统的各种肿瘤类型中得到了很好的表征。在神经系统肿瘤中，Merlin介导接触抑制、侵袭、细胞生长，还阻碍增殖。最近的证据还表明，Merlin蛋白在翻译后修饰后在上述肿瘤类型中迅速降解，包括Akt介导的磷酸化，然后是泛素化。梅林在乳腺癌方面的研究不足。有趣的是，我们还发现Merlin对OPN有负调节作用。基于这些发现，我们假设Merlin和OPN β相互调节。两种蛋白质水平之间的平衡对于维持非恶性细胞行为至关重要。Merlin在未转化的细胞中保持OPN水平处于检查状态。在乳腺癌的发病过程中，已知OPN水平会增加（由于多种异常信号传导途径）。我们认为，通过OPN的信号传导，激活磷酸化Akt磷酸化Merlin。磷酸化Merlin靶向蛋白酶体降解。因此，随着乳腺癌的进展，OPN的增加降低了Merlin的稳定性，导致细胞中Merlin的总体减少。这破坏了Merlin和OPN之间的正常生理平衡。这种恶性循环促进了乳腺癌的恶性进展。我们的总体目标是（i）阐明Merlin在乳腺癌中的意义，（ii）了解Merlin和OPN在乳腺癌中的相互调节机制。为此，我们提出了以下具体目标。 具体目标1： 验证通过调节Merlin水平我们可以调节乳腺癌细胞恶性行为的假设。 具体目标二： 了解Merlin和OPN在乳腺癌中相互调节的机制。 具体目标3： 确定患者来源的乳腺癌标本中OPN和Merlin表达之间的相关性。 预期成果和影响：拟议的研究将有助于更好地了解Merlin在乳腺癌进展中的作用，并将揭示OPN和Merlin之间的阴阳关系。潜在地使用Akt/PI-3-激酶和蛋白酶体抑制剂来稳定Merlin蛋白的能力是可以在患者中探索以恢复Merlin的生长抑制活性的治疗方式。

DESCRIPTION (provided by applicant): The oncoprotein, osteopontin (OPN) expressed by tumor cells potentiates their malignant properties, specifically by affecting their ability to grow, invade, and metastasize. Our research shows that OPN downregulates the protein levels of the tumor suppressor protein, Merlin, likely by targeting it for degradation in breast cancer cells. Merlin is a tumor suppressor gene that has been well characterized in various tumor types of the nervous system. In nervous system tumors, Merlin mediates contact inhibition, invasion, cell growth and also impedes proliferation. Recent evidence also implicates that Merlin protein gets degraded rapidly in the above tumor types following post-translation modifications, including Akt-mediated phosphorylation followed by ubiquitination. Merlin is understudied in breast cancer. Interestingly, we also discovered that Merlin exerts a negative regulatory effect on OPN. Based on these findings, we hypothesize that Merlin and OPN reciprocally regulate each other. A balance between the levels of the two proteins is critical to the maintenance of non-malignant cell behavior. Merlin keeps OPN levels under check in untransformed cells. During the pathogenesis of breast cancer OPN levels are known to increase (as a result of multiple aberrant signaling pathways). We propose that following signaling via OPN, activated phospho-Akt phosphorylates Merlin. Phosphorylated Merlin is targeted for proteasomal degradation. Thus, with the advancement of breast cancer, the increase in OPN decreases stability of Merlin, resulting in an overall decreased pool of Merlin in the cells. This disrupts the normal physiological balance between Merlin and OPN. This vicious cycle promotes malignant progression of breast cancer. Our overall objectives are (i) to elucidate the significance of Merlin in breast cancer and, (ii) to understand the mechanism of reciprocal regulation of Merlin and OPN in breast cancer. Towards this, we have proposed the following Specific Aims. Specific Aim 1: Test the hypothesis that by modulating Merlin levels we can regulate the malignant behavior of breast cancer cells. Specific Aim 2: Understand the mechanism of reciprocal regulation of Merlin and OPN in breast cancer. Specific Aim 3: Determine the correlation between expression of OPN and Merlin in patient-derived breast cancer specimens. Expected outcome & Impact: The proposed studies will lead to a better understanding of the role of Merlin in breast cancer progression & will reveal a yin-and-yang relationship between the OPN and Merlin. The ability to potentially use Akt/PI-3-kinase and proteasome inhibitors to stabilize Merlin protein is a treatment modality that can be explored in patients to reinstate the growth-inhibitory activity of Merlin.